Gilead Sciences (GILD) Suffers a Larger Drop Than the General Market: Key Insights

Company Performance - Gilead Sciences (GILD) closed at $105.87, down 1.53% from the previous trading day, underperforming the S&P 500's loss of 0.22% [1] - Over the past month, Gilead's shares have decreased by 0.13%, which is better than the Medical sector's loss of 0.63% and the S&P 500's loss of 7.48% [1] Earnings Forecast - Gilead is expected to report an EPS of$ 1.73, representing a significant growth of 231.06% compared to the same quarter last year [2] - The Zacks Consensus Estimate for revenue is projected at $6.78 billion, reflecting a 1.36% increase from the previous year [2] Annual Estimates - For the entire year, earnings are forecasted at$ 7.87 per share, indicating a growth of 70.35%, while revenue is expected to be $28.55 billion, showing a slight decline of 0.7% compared to the previous year [3] - Recent analyst estimate revisions suggest a positive outlook for Gilead's business and profitability [3] Valuation Metrics - Gilead Sciences has a Forward P/E ratio of 13.67, which is lower than the industry's average Forward P/E of 19.05 [6] - The company has a PEG ratio of 0.7, compared to the industry average PEG ratio of 1.56, indicating a favorable valuation relative to projected earnings growth [6] Industry Context - The Medical - Biomedical and Genetics industry, which includes Gilead, has a Zacks Industry Rank of 75, placing it in the top 30% of over 250 industries [7] - Research indicates that higher-ranked industries tend to outperform lower-ranked ones by a factor of 2 to 1 [7]